Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815186 | 0.81 | PTGS2 (0.41) | PTGS2PBRM1HSD17B1MAOAMAOB | |
| SCHEMBL4814288 | 0.75 | PBRM1 (0.47) | PTGS2PBRM1MAOAMAOB | |
| SCHEMBL4816161 | 0.75 | MAOB (0.46) | HSD17B1MAOAMAOB | |
| SCHEMBL4814033 | 0.74 | HSD17B1 (0.42) | PTGS2PBRM1HSD17B1MAOAMAOB | |
| SCHEMBL1273997 | 0.71 | PBRM1 (0.47) | PTGS2PBRM1HSD17B1PTGS1 | |
| SCHEMBL4817719 | 0.71 | MAOA (0.32) | MAOAMAOB | |
| SCHEMBL4813809 | 0.71 | — | — | |
| SCHEMBL866242 | 0.68 | HSD17B1 (0.51) | PTGS2PBRM1HSD17B1MAOBPTGS1 | |
| SCHEMBL4814155 | 0.68 | SMN1; SMN2 (0.45) | — | |
| SCHEMBL4811875 | 0.67 | PBRM1 (0.41) | PTGS2PBRM1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1740579-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | PTGS2 1985/4885PBRM1 988/4885HSD17B1 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.